Cargando…

Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis

BACKGROUND: As a pivotal regulator, cyclin D3 gives play to a crucial value in conversion from the G1 stage to the S stage of cell cycle, which is implicated in tumor progression, especially proliferation and migration. Recent literatures have reported that cyclin D3 could predict survival time of m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bo, Wang, Zijian, Han, Lizhi, Gong, Song, Wang, Yanxue, He, Zhiwen, Feng, Yong, Yang, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558842/
https://www.ncbi.nlm.nih.gov/pubmed/31198407
http://dx.doi.org/10.1186/s12935-019-0865-3
_version_ 1783425713892753408
author Wang, Bo
Wang, Zijian
Han, Lizhi
Gong, Song
Wang, Yanxue
He, Zhiwen
Feng, Yong
Yang, Zhaohui
author_facet Wang, Bo
Wang, Zijian
Han, Lizhi
Gong, Song
Wang, Yanxue
He, Zhiwen
Feng, Yong
Yang, Zhaohui
author_sort Wang, Bo
collection PubMed
description BACKGROUND: As a pivotal regulator, cyclin D3 gives play to a crucial value in conversion from the G1 stage to the S stage of cell cycle, which is implicated in tumor progression, especially proliferation and migration. Recent literatures have reported that cyclin D3 could predict survival time of malignancy patients. But, its prognostic role of cyclin D3 in neoplasms remains controversial. METHODS: Databases involving EMBASE, PubMed and Web of Science were carefully searched, and literatures investigating the prognostic effect of aberrantly expressing cyclin D3 among human cancers were collected for further analysis. We used both hazards ratios and its corresponding 95% confidence intervals to evaluate the connection among the survival rate of malignancy patients and the expression of cyclin D3. RESULTS: There were 13 eligible researches involving 16 cohorts and 2395 participants which were included in this study. The outcomes suggested that highly expressing cyclin D3 was significantly correlated with worse clinical prognosis of overall survival (HR 1.88; 95% CI 1.31–2.69) and disease specific survival (HR 2.68; 95% CI 1.35–5.31). But there existed no significant connection between the elevated expression of cyclin D3 with disease free survival (HR 2.65; 95% CI 0.83–8.46), recurrence-free survival (HR 2.86; 95% CI 0.82–9.96) and progression-free survival (HR 5.24; 95% CI 0.46–60.25) of diffident kinds of malignancy patients. Moreover, we discovered that elevated cyclin D3 expression was significantly connected with decreased overall survival in lymphoma (HR 3.72; 95% CI 2.18–6.36) while no significant relevance between highly expressing cyclin D3 and the overall survival in breast cancer was obtained (HR 2.12; 95% CI 0.76–5.91). CONCLUSIONS: This meta-analysis demonstrated that highly expressing cyclin D3 might be an unfavorable prognostic biomarker for various malignancy patients, which can make great contributions to the clinical diagnosis and treatment.
format Online
Article
Text
id pubmed-6558842
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65588422019-06-13 Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis Wang, Bo Wang, Zijian Han, Lizhi Gong, Song Wang, Yanxue He, Zhiwen Feng, Yong Yang, Zhaohui Cancer Cell Int Review BACKGROUND: As a pivotal regulator, cyclin D3 gives play to a crucial value in conversion from the G1 stage to the S stage of cell cycle, which is implicated in tumor progression, especially proliferation and migration. Recent literatures have reported that cyclin D3 could predict survival time of malignancy patients. But, its prognostic role of cyclin D3 in neoplasms remains controversial. METHODS: Databases involving EMBASE, PubMed and Web of Science were carefully searched, and literatures investigating the prognostic effect of aberrantly expressing cyclin D3 among human cancers were collected for further analysis. We used both hazards ratios and its corresponding 95% confidence intervals to evaluate the connection among the survival rate of malignancy patients and the expression of cyclin D3. RESULTS: There were 13 eligible researches involving 16 cohorts and 2395 participants which were included in this study. The outcomes suggested that highly expressing cyclin D3 was significantly correlated with worse clinical prognosis of overall survival (HR 1.88; 95% CI 1.31–2.69) and disease specific survival (HR 2.68; 95% CI 1.35–5.31). But there existed no significant connection between the elevated expression of cyclin D3 with disease free survival (HR 2.65; 95% CI 0.83–8.46), recurrence-free survival (HR 2.86; 95% CI 0.82–9.96) and progression-free survival (HR 5.24; 95% CI 0.46–60.25) of diffident kinds of malignancy patients. Moreover, we discovered that elevated cyclin D3 expression was significantly connected with decreased overall survival in lymphoma (HR 3.72; 95% CI 2.18–6.36) while no significant relevance between highly expressing cyclin D3 and the overall survival in breast cancer was obtained (HR 2.12; 95% CI 0.76–5.91). CONCLUSIONS: This meta-analysis demonstrated that highly expressing cyclin D3 might be an unfavorable prognostic biomarker for various malignancy patients, which can make great contributions to the clinical diagnosis and treatment. BioMed Central 2019-06-10 /pmc/articles/PMC6558842/ /pubmed/31198407 http://dx.doi.org/10.1186/s12935-019-0865-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wang, Bo
Wang, Zijian
Han, Lizhi
Gong, Song
Wang, Yanxue
He, Zhiwen
Feng, Yong
Yang, Zhaohui
Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis
title Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis
title_full Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis
title_fullStr Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis
title_full_unstemmed Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis
title_short Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis
title_sort prognostic significance of cyclin d3 expression in malignancy patients: a meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558842/
https://www.ncbi.nlm.nih.gov/pubmed/31198407
http://dx.doi.org/10.1186/s12935-019-0865-3
work_keys_str_mv AT wangbo prognosticsignificanceofcyclind3expressioninmalignancypatientsametaanalysis
AT wangzijian prognosticsignificanceofcyclind3expressioninmalignancypatientsametaanalysis
AT hanlizhi prognosticsignificanceofcyclind3expressioninmalignancypatientsametaanalysis
AT gongsong prognosticsignificanceofcyclind3expressioninmalignancypatientsametaanalysis
AT wangyanxue prognosticsignificanceofcyclind3expressioninmalignancypatientsametaanalysis
AT hezhiwen prognosticsignificanceofcyclind3expressioninmalignancypatientsametaanalysis
AT fengyong prognosticsignificanceofcyclind3expressioninmalignancypatientsametaanalysis
AT yangzhaohui prognosticsignificanceofcyclind3expressioninmalignancypatientsametaanalysis